{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:35:32Z","timestamp":1791182132816,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Ministry of Health, Labour and Welfare of Japan"},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology (KK) of Japan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Kanzawa Medical Research Foundation (KK)"},{"name":"Okinawa New Industry Creation Project (TS)"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.vaccine.2014.09.020","type":"journal-article","created":{"date-parts":[[2014,9,22]],"date-time":"2014-09-22T16:15:50Z","timestamp":1411402550000},"page":"6233-6239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients"],"prefix":"10.1016","volume":"32","author":[{"given":"Kei","family":"Kawana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Tomio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Arimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terufumi","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Wada-Hiraike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutoshi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomitsu","family":"Sewaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Osuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2014.09.020_bib0005","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","article-title":"Papillomavirus and cancer: from basic studies to clinical application","volume":"2","author":"zur Hausen","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.vaccine.2014.09.020_bib0010","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":"Prevalence of HPV infection among females in the United States","volume":"297","author":"Dunne","year":"2007","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.vaccine.2014.09.020_bib0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/oxfordjournals.jncimonographs.a003479","article-title":"Human papillomavirus and cervical cancer\u2014burden and assessment of causality","volume":"31","author":"Bosch","year":"2003","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"2","key":"10.1016\/j.vaccine.2014.09.020_bib0020","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ygyno.2004.05.011","article-title":"Dominant human papillomavirus 16 infection in cervical neoplasia in young Japanese women; study of 881 outpatients","volume":"94","author":"Masumoto","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.vaccine.2014.09.020_bib0025","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1002\/ijc.22195","article-title":"Do we need a different strategy for HPV screening and vaccination in East Asia?","volume":"119","author":"Miura","year":"2006","journal-title":"Int J Cancer"},{"issue":"21","key":"10.1016\/j.vaccine.2014.09.020_bib0030","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"issue":"9686","key":"10.1016\/j.vaccine.2014.09.020_bib0035","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2014.09.020_bib0040","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of Human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Mu\u00f1oz","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.vaccine.2014.09.020_bib0045","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"issue":"9518","key":"10.1016\/j.vaccine.2014.09.020_bib0050","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2014.09.020_bib0055","first-page":"341","article-title":"Human papillomavirus vaccines: current issues and future: review","volume":"130","author":"Kawana","year":"2009","journal-title":"Indian J Med Res"},{"issue":"2","key":"10.1016\/j.vaccine.2014.09.020_bib0060","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ijc.23252","article-title":"Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions","volume":"122","author":"Kanodia","year":"2008","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.vaccine.2014.09.020_bib0065","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ygyno.2007.04.038","article-title":"Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III","volume":"106","author":"Einstein","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.vaccine.2014.09.020_bib0070","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ygyno.2007.05.038","article-title":"A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia","volume":"106","author":"Roman","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.vaccine.2014.09.020_bib0075","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/ijc.23022","article-title":"Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2\/3)","volume":"121","author":"Kaufmann","year":"2007","journal-title":"Int J Cancer"},{"issue":"18","key":"10.1016\/j.vaccine.2014.09.020_bib0080","first-page":"6032","article-title":"Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16\/18 oncoproteins","volume":"63","author":"Davidson","year":"2003","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.vaccine.2014.09.020_bib0085","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/ijgc-00009577-200605000-00020","article-title":"Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial","volume":"16","author":"Fiander","year":"2006","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/j.vaccine.2014.09.020_bib0090","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.cgt.7700937","article-title":"Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine","volume":"13","author":"Garc\u00eda-Hern\u00e1ndez","year":"2006","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2014.09.020_bib0095","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.AOG.0000110246.93627.17","article-title":"ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial","volume":"103","author":"Garcia","year":"2004","journal-title":"Obstet Gynecol"},{"issue":"19","key":"10.1016\/j.vaccine.2014.09.020_bib0100","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2014.09.020_bib0105","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ajog.2010.09.020","article-title":"Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy","volume":"204","author":"Brun","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"155","key":"10.1016\/j.vaccine.2014.09.020_bib0110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004414","article-title":"Immunotherapy against HPV16\/18 generates potent TH1 and cytotoxic cellular immune responses","volume":"4","author":"Bagarazzi","year":"2012","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.vaccine.2014.09.020_bib0115","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/1078-0432.CCR-08-1725","article-title":"A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2\/3","volume":"15","author":"Trimble","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.vaccine.2014.09.020_bib0120","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2174\/156652409789105525","article-title":"Role of beta7 integrins in intestinal lymphocyte homing and retention","volume":"9","author":"Gorfu","year":"2009","journal-title":"Curr Mol Med"},{"issue":"5","key":"10.1016\/j.vaccine.2014.09.020_bib0125","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1600-0897.2011.01041.x","article-title":"Characterization of gut-derived intraepithelial lymphocyte (IEL) residing in human papillomavirus (HPV)-infected intraepithelial neoplastic lesions","volume":"66","author":"Kojima","year":"2011","journal-title":"Am J Reprod Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2014.09.020_bib0130","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.4049\/jimmunol.175.11.7297","article-title":"A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors","volume":"175","author":"Berm\u00fadez-Humar\u00e1n","year":"2005","journal-title":"J Immunol"},{"issue":"36","key":"10.1016\/j.vaccine.2014.09.020_bib0135","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1016\/j.vaccine.2007.06.062","article-title":"Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria","volume":"25","author":"Cortes-Perez","year":"2007","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2014.09.020_bib0140","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/ijc.22035","article-title":"Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific antitumor effects in C57\/BL6 mice","volume":"119","author":"Poo","year":"2006","journal-title":"Int J Cancer"},{"issue":"16","key":"10.1016\/j.vaccine.2014.09.020_bib0145","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1016\/j.vaccine.2010.02.005","article-title":"Oral immunization with Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocyte against HPV16 E7","volume":"28","author":"Adachi","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2014.09.020_bib0150","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1128\/JCM.38.1.357-361.2000","article-title":"Improved amplification of genital human papillomaviruses","volume":"38","author":"Gravitt","year":"2000","journal-title":"J Clin Microbiol"},{"issue":"11","key":"10.1016\/j.vaccine.2014.09.020_bib0155","first-page":"3356","article-title":"A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix","volume":"7","author":"Follen","year":"2001","journal-title":"Clin Can Res"},{"issue":"10","key":"10.1016\/j.vaccine.2014.09.020_bib0160","first-page":"1029","article-title":"A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia","volume":"10","author":"Keefe","year":"2001","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"27","key":"10.1016\/j.vaccine.2014.09.020_bib0165","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/S0264-410X(01)00086-X","article-title":"Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens","volume":"19","author":"van der Burg","year":"2001","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2014.09.020_bib0170","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-1759(01)00464-1","article-title":"Evaluation of the cervical cytobrush sampling technique for the preparation of CD45+ mononuclear cells from the human cervix","volume":"258","author":"Prakash","year":"2001","journal-title":"J Immunol Methods"},{"issue":"11","key":"10.1016\/j.vaccine.2014.09.020_bib0175","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/jcp.37.11.1201","article-title":"Vulvar intraepithelial neoplasia and microinvasive carcinoma of the vulva","volume":"37","author":"Buckley","year":"1984","journal-title":"J Clin Pathol"},{"issue":"8","key":"10.1016\/j.vaccine.2014.09.020_bib0185","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1158\/1078-0432.CCR-06-2916","article-title":"HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions","volume":"13","author":"Peng","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.vaccine.2014.09.020_bib0190","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1158\/1078-0432.CCR-04-2599","article-title":"Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype","volume":"11","author":"Trimble","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.vaccine.2014.09.020_bib0195","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/j.1525-1438.2007.00938.x","article-title":"Association of human leukocyte antigen and T cell message with human papillomavirus 16-positive cervical neoplasia in Japanese women","volume":"17","author":"Saito","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.vaccine.2014.09.020_bib0200","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/eji.200425125","article-title":"CCL25\/CCR9 promotes the induction and function of CD103 on intestinal intraepithelial lymphocytes","volume":"34","author":"Ericsson","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2014.09.020_bib0205","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00004347-199304000-00018","article-title":"The natural history of cervical intraepithelial neoplasia: a critical review","volume":"12","author":"Ostor","year":"1993","journal-title":"Int J Gynecol Pathol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14012791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14012791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:20:38Z","timestamp":1759400438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14012791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":40,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0264410X14012791"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.09.020","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}